Status:
UNKNOWN
Study on the Use of Cinacalcet in Phosphocalcic Context.
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Hyperparathyroidism, Secondary
Hyperparathyroidism, Primary
Eligibility:
All Genders
Up to 99 years
Brief Summary
Currently, the indications used for MA (Marketing Authorization) Cinacalcet in France are hyperparathyroidism (hyperPTH) in adults, whether primary (for patients in whom parathyroidectomy is theoretic...
Eligibility Criteria
Inclusion
- Patients with phosphocalcic pathology without end-stage renal failure
- Patients followed in one of the hospitals of the centers of reference and competence of the diseases of the metabolism of calcium and phosphate
- For children under 18: patient and parent (s) / parent having been informed of the study and having expressed their on-opposition
- For adults: patient / legal guardian of the patient under guardianship having been informed of the study and expressing his or her non opposition
Exclusion
- Patient suffering from parathyroid cancer,
- Patient suffering from primary hyperPTH in whom parathyroidectomy would theoretically be indicated but contraindicated or clinically inappropriate,
- Patient suffering from hyperPTH secondary to end-stage renal failure
- No social security support
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04126954
Start Date
January 1 2020
End Date
December 1 2023
Last Update
October 15 2019
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Endocrinologie Diabète et Maladies Métaboliques - Hôpital Gabriel Montpied
Clermont-Ferrand, France
2
Service de Néphrologie Pédiatrique -Hôpital Jeanne de Flandre
Lille, France, 59037
3
Service d'Endocrinologie Pédiatrique - Hôpital de la mère et de l'Enfant
Limoges, France, 87042
4
Pole Femme Mère Enfant - Pédiatrie spécialisée - Centre Hospitalier Universitaire
Montpellier, France, 34090